Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01357
|
|||||
| Drug Name |
Olopatadine
|
|||||
| Synonyms |
Allelock; Opatanol; Pataday; Patanase; Patanol; OLOPATADINE HCl; OLOPATADINE HYDROCHLORIDE; ALO4943A; HCl of KW 4679; KW 4679; O0361; AL-4943A; ALO-4943A; Allelock (TN); KW-4679; KW-4943A; Olopatadine [INN:BAN]; Pataday (TN); Patanase (TN); Patanol S (TN); {(11Z)-11-[3-(dimethylamino)propylidene]-6,11-dihydrodibenzo[b,e]oxepin-2-yl}acetic acid; 11-((Z)-3-(Dimethylamino)propylidene)-6,11-dihydrodibenz(b,e)oxepin-2-acetic acid; 11-((Z)-3-(Dimethylamino)propylidene)-6,11-dihydrodibenz(b,e)oxepin-2-acetic acid hydrochloride; 11-((Z)-3-(Dimethylamino)propylidene)-6,11-dihydrodibenz(b,e)oxepin-2-acetic acid, hydrochloride; 11-(3-(dimethylamino)propylidene)-6,11-dihydrodibenz(b,e)oxepin-2-acetic acid; 2-[(11Z)-11-[3-(dimethylamino)propylidene]-6H-benzo[c][1]benzoxepin-2-yl]acetic acid; 2-[(11Z)-11-[3-(dimethylamino)propylidene]-6H-benzo[c][1]benzoxepin-2-yl]acetic acid hydrochloride
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Itching of the eye due to allergic conjunctivitis [ICD11: 9A60.02] | Approved | [1] | |||
| Therapeutic Class |
Antiallergic Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C21H23NO3
|
|||||
| Canonical SMILES |
CN(C)CCC=C1C2=CC=CC=C2COC3=C1C=C(C=C3)CC(=O)O
|
|||||
| InChI |
InChI=1S/C21H23NO3/c1-22(2)11-5-8-18-17-7-4-3-6-16(17)14-25-20-10-9-15(12-19(18)20)13-21(23)24/h3-4,6-10,12H,5,11,13-14H2,1-2H3,(H,23,24)/b18-8-
|
|||||
| InChIKey |
JBIMVDZLSHOPLA-LSCVHKIXSA-N
|
|||||
| CAS Number |
CAS 113806-05-6
|
|||||
| Pharmaceutical Properties | Molecular Weight | 337.4 | Topological Polar Surface Area | 49.8 | ||
| Heavy Atom Count | 25 | Rotatable Bond Count | 5 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 4 | |||
| XLogP |
1.5
|
|||||
| PubChem CID | ||||||
| PubChem SID |
9991
, 8616501
, 14851325
, 39289993
, 46506025
, 49830421
, 50064183
, 50339892
, 53788070
, 57357997
, 85209467
, 92308886
, 93166443
, 96024980
, 103916408
, 113854504
, 117867960
, 118048374
, 118313762
, 124974068
, 126682737
, 131839756
, 134338320
, 135076611
, 137005453
, 137233305
, 142121621
, 160964111
, 163669016
, 170499432
, 175266654
, 175435402
, 176484058
, 176484854
, 177749229
, 178103823
, 179149624
, 179225235
, 184623003
, 223655359
, 224131802
, 226396615
, 251916843
, 251918082
, 251960673
, 252391226
, 252429690
, 252671957
|
|||||
| ChEBI ID |
CHEBI:94593
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | Olopatadine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.